Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia.
Female
Humans
Human papillomavirus 16
Human papillomavirus 18
Human Papillomavirus Viruses
Neoplasm Recurrence, Local
/ epidemiology
Papillomaviridae
Papillomavirus Infections
/ diagnosis
Retrospective Studies
Uterine Cervical Dysplasia
/ diagnosis
Uterine Cervical Neoplasms
/ diagnosis
Multicenter Studies as Topic
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
10
10
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
To evaluate how the duration of human papillomavirus (HPV) persistence influences the risk of developing recurrent high-grade cervical dysplasia (CIN2+). Data of patients with persistent HPV infection (at least at 6 months) after primary conization were extracted from a multi-institutional Italian database, retrospectively. Kaplan-Meier and Cox proportional hazards models were used to evaluate associations between duration of HPV persistence with the 5-year risk of developing recurrent CIN2+. Overall, 545 patients met the inclusion criteria. Positive margins were detected in 160 (29.3%) patients. Overall, 247 (45.3%) and 123 (22.6%) patients had a documented infection from HPV16/18, and other high-risk HPV types. 187 (34.3%), 73 (13.4%), and 40 (7.3%) were diagnosed with persistent HPV infection at 12, 18, and 24 months, respectively. Patients with HPV persistence at 6 months experienced a risk of recurrence of 7.46%. Twelve-month HPV persistence strongly correlates with the risk of developing the recurrent disease (risk of recurrence: 13.1%). While, having HPV persistence >12 months did not correlate with an increased risk of recurrence (hazard ratio: 1.34 (95% confidence interval: 0.78-2.32); P = 0.336, log-rank test). HPV persistence is one of the most important factors predicting the risk of CIN2+ recurrence. The risk of CIN2+ recurrence increased with the increase of HPV persistence for up to 1 year. The persistence of HPV after the first year does not appear as a risk factor.
Identifiants
pubmed: 37401466
doi: 10.1097/CEJ.0000000000000822
pii: 00008469-990000000-00078
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-532Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bogani G, Tagliabue E, Ferla S, Martinelli F, Ditto A, Chiappa V, et al. (2019). Nomogram-based prediction of cervical dysplasia persistence/recurrence. Eur J Cancer Prev 28:435–440.
Bogani G, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Lopez S, et al. 2020a). Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: a 5-year follow-up study. Gynecol Oncol 159:636–641.
Bogani G, Raspagliesi F, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, et al. 2020b). Assessing the long-term role of vaccination against HPV after loop electrosurgical excision procedure (LEEP): a propensity-score matched comparison. Vaccines (Basel) 8:717.
Bogani G, Raspagliesi F, di Donato V, Brusadelli C, Guerrisi R, Pinelli C, et al. 2021a). Spotlight on the role of human papillomavirus vaccines. Gynecol Oncol 160:346–350.
Bogani G, Sopracordevole F, Di Donato V, Ciavattini A, Ghelardi A, Lopez S, et al. 2021b). High-risk HPV-positive and -negative high-grade cervical dysplasia: analysis of 5-year outcomes. Gynecol Oncol 161:173–178.
Bogani G, Lalli L, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, et al. (2022). Development of a nomogram predicting the risk of persistence/recurrence of cervical dysplasia. Vaccines (Basel) 10:579.
Bogani G, Ghelardi A, Sopracordevole F, Annoni M, Ciavattini A, Giannella L, et al. (2023). Human papillomavirus (HPV) vaccination: a call for action in Italy. Int J Gynecol Cancer:ijgc-2023-004275. doi: 10.1016/j.ygyno.2020.08.034.
doi: 10.1016/j.ygyno.2020.08.034
Bukowski A, Hoyo C, Hudgens MG, Brewster WR, Valea F, Bentley RC, et al. (2022). Extended human papillomavirus genotyping to predict progression to high-grade cervical precancer: a prospective cohort study in the southeastern United States. Cancer Epidemiol Biomarkers Prev cebp.0054.2022-1-15 10:41:07.593. doi: 10.1158/1055-9965.EPI-22-0054.
doi: 10.1158/1055-9965.EPI-22-0054
Casarin J, Bogani G, Serati M, Pinelli C, Laganà AS, Garzon S, et al. (2020). Presence of glandular cells at the preoperative cervical cytology and local recurrence in endometrial cancer. Int J Gynecol Pathol 39:522–528.
Ciavattini A, Di Giuseppe J, Marconi C, Giannella L, Delli Carpini G, Paolucci M, et al. (2022). Hysterectomy for cervical intraepithelial neoplasia: a retrospective observational multi-institutional study. Int J Gynaecol Obstet. 159:679–688.
Cicconi P, Wells C, McCarthy B, Wareing S, Andersson MI, Fox J, et al. (2022). Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): a feasibility study in women living with HIV in the UK. HIV Med 23:390–396.
Demarco M, Egemen D, Hyun N, Chen X, Moscicki AB, Cheung L, et al. (2022). Contribution of etiologic cofactors to CIN3+ risk among women with human papillomavirus-positive screening test results. J Low Genit Tract Dis 26:127–134.
Di Donato V, Caruso G, Bogani G, Cavallari EN, Palaia G, Perniola G, et al. (2022). HPV vaccination after primary treatment of HPV-related disease across different organ sites: a multidisciplinary comprehensive review and meta-analysis. Vaccines (Basel) 10:239.
Di Donato V, Bogani G, Casarin J, Ghezzi F, Malzoni M, Falcone F, et al. (2023). Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for ‘low-risk’ early-stage cervical cancer: a propensity-score based analysis. Gynecol Oncol 174:49–54.
Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. (2020). Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis 24:132–143.
Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. (2021). The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 398:2084–2092.
Firichenko SV, Stark M, Mynbaev OA (2021). The impact of cervical conization size with subsequent cervical length changes on preterm birth rates in asymptomatic singleton pregnancies. Sci Rep 11:19703.
Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, et al. (2023). Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization. Vaccines (Basel) 11:698.
IARC working group (2020). Monographs. Human papillomaviruses. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B-11.pdf . [Accessed 7 July 2020]
Lebeau A, Bruyere D, Roncarati P, Peixoto P, Hervouet E, Cobraiville G, et al. (2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nat Commun 13:1076.
Leung S, Vitonis A, Feldman S (2020). Yield of loop electrosurgical excision procedure (LEEP) among patients with and without known high-grade cervical dysplasia. Gynecol Oncol 159:194.
Mix J, Saraiya M, Hallowell BD, Befano B, Cheung LC, Unger ER, et al. (2022). Cervical precancers and cancers attributed to HPV types by race and ethnicity: implications for vaccination, screening, and management. J Natl Cancer Inst 114:845–853
Pan S, Wei W, Du X, Li Z, Tuo J, Zhang M, et al. (2022). Factors associated with persistence and clearance of HPV16/18 among rural Chinese women: a cohort study in Wufeng, Hubei province. Women Health 62:276–286.
Prétet JL, Dalstein V, Touzé A, Beby-Defaux A, Soussan P, Jacquin E, et al. (2022). High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: the Papillophar study. Clin Exp Med 23:87–96
Smith MA, Sherrah M, Sultana F, Castle PE, Arbyn M, Gertig D, et al. (2022). National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. BMJ 376:e068582.
Wentzensen N, Wilson LE, Wheeler CM, Carreon JD, Gravitt PE, Schiffman M, et al. (2010). Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res 70:8578–8586.